Corcept submits new drug application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer

14 July 2025 - Corcept Therapeutics has submitted a new drug application to the US FDA for its proprietary, selective ...

Read more →

Egetis receives FDA breakthrough therapy designation for tiratricol for MCT8 deficiency

15 July 2025 - Egetis Therapeutics today announced that the US FDA has granted breakthrough therapy designation for tiratricol, as ...

Read more →

Taxis Pharmaceuticals earns FDA QIDP designation for TXA14007, an investigational efflux pump inhibitor to combat antibiotic resistant pneumonia

15 July 2025 - Taxis Pharmaceuticals announced today that it has received an FDA qualified infectious disease product designation for TXA14007, ...

Read more →

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty, the first and only interchangeable rapid acting insulin aspart in the US

15 July 2025 - Biocon Biologics today announced that the US FDA has approved Kirsty (insulin aspart-xjhz), 100 units/mL as the ...

Read more →

Regulatory and clinical outcomes of non-oncology accelerated approvals

14 July 2025 - The US FDA accelerated approval pathway expedites drug approvals based on changes to surrogate or intermediate measures ...

Read more →

US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk

14 July 2025 - FDA decision anticipated H1, 2026 ...

Read more →

Sun Pharma announces launch of Leqselvi (deuruxolitinib) in the US for the treatment of severe alopecia areata

14 July 2025 - Leqselvi now available for prescription in US nationwide, offering a new option for eligible patients ...

Read more →

Atara Biotherapeutics provides regulatory and business updates on tabelecleucel

14 July 2025 - Atara Biotherapeutics resubmits tabelecleucel biologics license application for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease to ...

Read more →

US FDA approves finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥40%

14 July 2025 - New indication approval follows the US FDA’s priority review designation and is based on positive results from ...

Read more →

FDA grants Zenith’s ZEN-3694 fast track status

14 July 2025 - Zenith Epigenetics is pleased to announce the designation of ZEN-3694 as a fast track product by the ...

Read more →

Moderna receives full US FDA approval for COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years at increased risk for COVID-19 disease

10 July 2025 - Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 ...

Read more →

Milestone Pharmaceuticals announces FDA acceptance of the company’s response to the CRL for Cardamyst (etripamil) nasal spray

11 July 2025 - New PDUFA action date of 13 December 2025. ...

Read more →

Ultragenyx receives complete response letter from FDA for UX111 AAV gene therapy to treat Sanfilippo syndrome type A

11 July 2025 - complete response letter cited specific chemistry, manufacturing and controls related observations that are resolvable. ...

Read more →

Transcend Therapeutics receives breakthrough therapy designation for TSND- 201 (methylone) for the treatment of PTSD

10 July 2025 - Company planning to initiate Phase 3 program. ...

Read more →

FDA grants fast track designation for TRE-515 in combination with radiation therapy for the treatment of metastatic castration resistant prostate cancer

9 July 2025 - Trethera announced today that the US FDA has granted fast track designation for its novel drug, TRE-515, ...

Read more →